Insider Shareholders with Direct Ownership of Blueprint Medicines Corp (BPMC)
This section provides a comprehensive overview of the insiders with direct ownership of Blueprint Medicines Corp (BPMC). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Blueprint Medicines Corp Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Kate Haviland
CHIEF EXECUTIVE OFFICER |
187,105 | 45,365 | 184,578 $16.6 Million | 25 |
Mar 01, 2025
Added 16.02%
|
478,415 | 467,453 | 152,396 $13.7 Million | 75 |
Jan 21, 2025
Reduced 0.13%
|
|
Fouad Namouni
PRESIDENT, R & D |
103,762 | 21,492 | 82,270 $7.4 Million | 13 |
Mar 01, 2025
Added 13.83%
|
Michael Landsittel
CHIEF FINANCIAL OFFICER |
109,743 | 48,885 | 78,208 $7.03 Million | 19 |
Mar 01, 2025
Added 12.33%
|
Christina Rossi
CHIEF OPERATING OFFICER |
80,887 | 23,217 | 78,035 $7.02 Million | 18 |
Mar 01, 2025
Added 14.47%
|
9,692 | 0 | 74,160 $6.67 Million | 4 |
Jun 12, 2024
Added 2.93%
|
|
Tracey L Mc Cain
EVP AND CHIEF LEGAL OFFICER |
96,562 | 48,123 | 71,845 $6.46 Million | 16 |
Mar 01, 2025
Added 13.28%
|
Percy H. Carter
CHIEF SCIENTIFIC OFFICER |
74,093 | 13,698 | 60,395 $5.43 Million | 12 |
Mar 01, 2025
Added 15.41%
|
20,601 | 9,815 | 58,026 $5.22 Million | 6 |
Jun 12, 2024
Added 3.72%
|
|
Debra Durso Bumpus
CHIEF PEOPLE OFFICER |
146,069 | 110,541 | 54,763 $4.92 Million | 24 |
Mar 01, 2025
Added 16.73%
|
Philina Lee
CHIEF COMMERCIAL OFFICER |
79,921 | 54,546 | 45,729 $4.11 Million | 10 |
Mar 01, 2025
Added 19.39%
|
L. Becker Hewes
CHIEF MEDICAL OFFICER |
93,436 | 70,422 | 40,514 $3.64 Million | 25 |
Mar 01, 2025
Added 21.35%
|
Christopher K. Murray
CHIEF TECHNICAL OPERATIONS |
44,000 | 23,995 | 33,853 $3.04 Million | 18 |
Mar 07, 2024
Reduced 6.93%
|
Anthony L. Boral
Chief Medical Officer |
19,183 | 10,000 | 28,147 $2.53 Million | 3 |
Dec 14, 2020
Reduced 0.76%
|
Ariel Hurley
PRINCIPAL ACCOUNTING OFFICER |
51,251 | 44,285 | 18,270 $1.64 Million | 45 |
Mar 03, 2025
Reduced 5.56%
|
47,419 | 32,727 | 18,254 $1.64 Million | 17 |
Jun 12, 2024
Added 10.94%
|
|
Marion Dorsch
Chief Scientific Officer |
16,778 | 16,778 | 15,250 $1.37 Million | 6 |
Feb 22, 2021
Reduced 33.2%
|
9,692 | 0 | 13,254 $1.19 Million | 4 |
Jun 12, 2024
Added 14.47%
|
|
7,442 | 0 | 10,842 $974,912 | 3 |
Jun 12, 2024
Added 17.14%
|
|
8,742 | 0 | 8,742 $786,080 | 3 |
Jun 12, 2024
Added 20.41%
|
|
8,742 | 0 | 8,742 $786,080 | 3 |
Jun 12, 2024
Added 20.41%
|
|
4,860 | 768 | 8,412 $756,407 | 5 |
Jun 21, 2022
Added 23.61%
|
|
Charles A Rowland Jr
Director |
23,159 | 20,909 | 5,812 $522,615 | 7 |
Jun 02, 2021
Added 27.91%
|
Tango Therapeutics, Inc.
Director |
3,400 | 0 | 3,400 $305,728 | 1 |
Dec 08, 2021
Added 50.0%
|
18,504 | 19,824 | 2,242 $201,600 | 7 |
Nov 21, 2024
Reduced 81.42%
|